Oxford BioMedica plc operates within the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Oxford BioMedica plc with three other
companies in this sector in the United Kingdom:
GW Pharmaceuticals PLC
sales of £10.32 million [US$13.38 million]
of which 63%
Circassia Pharmaceuticals PLC
(£23.10 million [US$29.96 million]
of which 100%
was operating-NIOX), and
(£12.03 million [US$15.61 million]
of which 67%
was Research and development).
During the year ended December of 2016, sales at
Oxford BioMedica plc were £27.78 million (US$36.03 million).
increase of 74.6%
versus 2015, when the company's sales were £15.91 million.
This was the third consecutive year of growth at Oxford BioMedica plc.